United Imaging Healthcare's 2Q26 Revenue Met Expectations While Profit Was Under Pressure; Overseas Acceleration and Product Upgrades Remain the Main Highlights

Overview

This report reviews United Imaging Healthcare's 2Q26 results and subsequent growth drivers. Revenue was in line with expectations while profit showed a modest shortfall, but Morgan Stanley believes the company continues to make positive progress in accelerating overseas expansion, gaining domestic market share, upgrading its product mix, and internalizing key components, leaving the core investment thesis largely unchanged.

Core views

2Q26 revenue grew 17.1% YoY, in line with Morgan Stanley's expectations, but net profit declined 21% YoY and missed expectations. The report characterizes this as a "modest miss" and believes the direction of consensus EPS expectations over the next 12 months will remain broadly unchanged. Excluding foreign-exchange effects, 1H26 net profit would have grown 8.8% YoY, indicating that currency effects were a significant distortion behind weak reported profit rather than the weakness being entirely attributable to operating deterioration. By product, all major product lines achieved growth: MR sales were Rmb2.29bn, up 16% YoY; CT was Rmb1.65bn, up 9%; MI was Rmb1.06bn, up 26%; XR was Rmb455mn, up 41%; and RT was Rmb397mn, up 64%. Faster-growing product lines shifted the mix in a more favorable direction. Overall gross margin reached 46.7% in 2Q26, up 0.6 percentage points YoY, as the improved product mix offset higher raw-material costs. The selling and administrative expense ratio declined 0.6 percentage points YoY, but the R&D expense ratio rose 4.3 percentage points YoY. Elevated R&D investment pressured current-period profit while also supporting the product-upgrade direction emphasized in the report. In the domestic market, the company's revenue grew 8.5% while the industry declined 8% over the same period, resulting in a 1.7 percentage-point market share gain. The company expects China's imaging equipment market to return to positive growth in 2H26, a significant improvement from the 8% decline in 1H26, mainly based on smoother execution of centralized procurement projects and accelerated deployment of fiscal support since July 2026. From January to July 2026, the company won 24.5% of centralized procurement project tenders, ranking first among all brands and leading the second-ranked brand by 3.2 percentage points. Although hospital procurement continues to face industry-wide pricing pressure, the company's blended ex-factory prices across product lines are still rising, driven by product-mix upgrades, indicating that its share expansion is not entirely reliant on price cuts. The overseas business is the report's most important positive signal. 1H26 overseas revenue reached Rmb1.77bn, up 54.5% YoY, implying approximately 80% YoY growth in 2Q26; management reiterated its target of more than 50% overseas revenue growth for the full year. By region, Asia-Pacific revenue was Rmb1.0bn, up 148% YoY; North American revenue was Rmb421mn, down slightly YoY due to delivery issues; and EU revenue was Rmb266mn, up 49% YoY, with rapid growth in major Western European countries. The company's cumulative installed base has exceeded 40,000 units, covering more than 100 countries and over 17,000 institutions, further expanding its international commercialization foundation. The overseas business's gross margin expanded by approximately 3.7 percentage points despite rising raw-material costs, with the report summary showing an increase of 3.77 percentage points. Several key countries had already achieved profitability as of 1H26, leading the report to conclude that overseas expansion is gradually transitioning from revenue growth to profit realization. Meanwhile, the company has continued to diversify its supply chain and internalize key components over the past several years, which both helps reduce the cost of sales and mitigates supply risks arising from potential geopolitical uncertainty. Morgan Stanley ModelWare forecasts EPS of Rmb2.28, Rmb2.65, Rmb3.32, and Rmb4.14 for 2025 through 2028, respectively; net revenue of Rmb13.8003bn, Rmb16.5061bn, Rmb19.4928bn, and Rmb22.8114bn, respectively; EBITDA of Rmb2.6791bn, Rmb3.1589bn, Rmb3.7548bn, and Rmb4.4960bn, respectively; and ModelWare net profit of Rmb1.8693bn, Rmb2.1713bn, Rmb2.7223bn, and Rmb3.3920bn, respectively. The valuation benchmark uses a DCF model beginning in 2026 to reflect the company's healthy long-term operating cash flow, with key assumptions of an 8.8% WACC, a 4.0% perpetual growth rate, and a 13.5% normalized corporate tax rate. The report assigns an Equal-weight rating, an Attractive industry view, and a target price of Rmb152, implying 40% upside from the closing price of Rmb108.65 on August 19, 2026.

Analysis framework

The report first compares 2Q26 revenue and profit with Morgan Stanley's expectations, then analyzes the profit variance by product, expense ratios, and gross margin. It subsequently assesses the recovery path of the Chinese market based on industry growth, centralized procurement tender share, and fiscal support, while analyzing overseas revenue, deliveries, gross margin, and profitability progress by region. Finally, it uses ModelWare earnings forecasts and DCF valuation to translate operating trends into a target price and relative rating assessment.

Methodology notes

• Event-Driven Strategies and Behavioral FinanceExpectation Gap/Expectation Management

  Comparison of results with institutional expectations

  The report separately assesses whether revenue met expectations and whether profit missed expectations, and evaluates whether these variances would alter the core thesis and the direction of consensus EPS expectations over the next 12 months.

• Industry/Sector Analysis FrameworkVolume-price decomposition

  Breakdown of revenue, pricing, and gross margin by product and region

  The report breaks down growth across MR, CT, MI, XR, and RT, as well as China, Asia Pacific, North America, and the EU, and explains revenue quality and gross-margin performance using blended ex-factory prices and product-mix changes.

• Industry/Sector Analysis FrameworkSupply-demand framework

  Analysis of imaging equipment demand, centralized procurement execution, and fiscal support

  Based on the industry's decline in 1H26, improved execution of centralized procurement in 2H26, and accelerating fiscal support, the report concludes that demand for imaging equipment in China may shift from contraction to positive growth.

• Valuation MethodDCF Discounted Cash Flow

  Discounted cash flow valuation beginning in 2026

  The report derives its valuation benchmark from the discounted value of future operating cash flows, assuming an 8.8% WACC, a 4.0% perpetual growth rate, and a 13.5% normalized corporate tax rate.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Shanghai United Imaging Healthcare Co (688271.SS, 688271 CH)

  The direct subject of the report; overseas expansion, domestic market share gains, and product upgrades are the main positive drivers, while the 2Q26 profit miss represents near-term pressure.

  Strengths

  The domestic business grew against the industry trend and gained share; centralized procurement tender share ranked first; overseas revenue grew rapidly and several key countries have achieved profitability; gross margin remained resilient; and the supply chain has been diversified while key components have been internalized.

  Weaknesses

  2Q26 net profit declined 21% YoY and missed expectations; the R&D expense ratio rose 4.3 percentage points YoY; and the North American business declined slightly due to delivery issues.

  Comparison

  The China business grew 8.5% while the industry declined 8%; centralized procurement tender share was 24.5% from January to July 2026, leading the second-ranked brand by 3.2 percentage points.

  Risks

  Unexpected regulatory tightening, weaker government support for capital expenditure, loss of market share, deterioration in operating margins due to an unfavorable product mix, slower-than-expected overseas expansion and recurring revenue growth, and geopolitical risks.

Key data

• 2Q26 Revenue Growth+17.1% YoYIn line with Morgan Stanley's expectations
• 2Q26 Net Profit Growth-21% YoYBelow Morgan Stanley's expectations
• 1H26 Net Profit Growth Excluding Foreign-Exchange Effects+8.8% YoYPerformance adjusted for foreign-exchange effects as presented in the report
• 2Q26 Gross Margin46.7%Up 0.6 percentage points YoY
• Product-Line SalesMR Rmb2.29bn; CT Rmb1.65bn; MI Rmb1.06bn; XR Rmb455mn; RT Rmb397mnUp 16%, 9%, 26%, 41%, and 64% YoY, respectively
• China Business Growth+8.5% YoYThe industry declined 8% over the same period, while the company's share rose 1.7 percentage points
• Centralized Procurement Project Tender Share24.5%Ranked first from January to July 2026, leading the second-ranked brand by 3.2 percentage points
• 1H26 Overseas RevenueRmb1.77bnUp 54.5% YoY, implying approximately 80% YoY growth in 2Q26
• 1H26 Overseas Regional RevenueAsia Pacific Rmb1.0bn; North America Rmb421mn; EU Rmb266mnUp 148%, down slightly, and up 49% YoY, respectively
• Global Installed-Base CoverageMore than 40k units, over 100 countries, and more than 17,000 institutionsCumulative scale as of the point in time stated in the report
• 2025—2028 EPSRmb2.28, Rmb2.65, Rmb3.32, Rmb4.142026—2028 are Morgan Stanley estimates
• Key DCF AssumptionsWACC 8.8%; perpetual growth rate 4.0%; normalized corporate tax rate 13.5%The DCF model begins in 2026
• Target Price and UpsideRmb152.00; 40%Based on the August 19, 2026 closing price of Rmb108.65

Impact & implications

The report believes that the near-term profit miss is not sufficient to alter its core view: the domestic business continued to gain share despite industry contraction, while overseas growth and gross-margin improvement provide support for future profit realization. Future earnings delivery depends on whether China's imaging equipment market can return to positive growth in 2H26, whether the target of more than 50% overseas growth can be achieved, and whether product-mix improvements can continue to offset cost and hospital-side pricing pressures.

Risks

• The regulatory environment may tighten more than expected.
• Government support for capital expenditure may weaken.
• The company may lose market share.
• Unfavorable product-mix changes may lead to deterioration in operating margins.
• Overseas expansion and recurring revenue growth may be slower than expected.
• Geopolitical risks may affect the business and supply chain.

What to watch

• Watch whether China's imaging equipment market can shift from an 8% decline in 1H26 to positive growth in 2H26.
• Watch the execution of centralized procurement projects, the deployment of fiscal support, and whether the company's 24.5% tender share can be sustained.
• Watch whether the full-year target of more than 50% overseas revenue growth can be achieved.
• Watch whether North American delivery issues ease and whether growth in Asia Pacific and the EU can be sustained.
• Watch further improvements in profitability in key overseas countries, recurring revenue, and overseas gross margin.
• Watch whether product-mix upgrades can continue to raise blended ex-factory prices and offset raw-material cost pressures.